Discordance rates between Trofile ® test and short-term virological response to maraviroc

Antiviral Research

Volumn 89, Issue 2, 2011, Pages 182-185

  Genebat, Miguel ^a   Ruiz Mateos, Ezequiel ^a   González Serna, Alejandro ^a   Pulido, Ildefonso ^a   Muñoz Fernández, M Ángeles ^b   Ferrando Martínez, Sara ^a   Leal, Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Clinical approach; Maraviroc; Tropism assay

Indexed keywords

MARAVIROC;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; ASSAY; CLINICAL ARTICLE; ENHANCED SENSITIVITY TROFILE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHENOTYPE; PRIORITY JOURNAL; VIRAL TROPISM; VIRUS EXAMINATION; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHILD; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIAZOLES; VIRAL TROPISM; YOUNG ADULT;

EID: 78751625145     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.11.015     Document Type: Article

References (12)

1. Chueca N., Garrido C., Alvarez M., Poveda E., de Dios Luna J., Zahonero N., Hernández-Quero J., Soriano V., Maroto C., de Mendoza C., García F. Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. J. Med. Virol. 2009, 81:763-767.
2. Fätkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., Saag M.S., Goebel F.D., Rockstroh J.K., Dezube B.J., Jenkins T.M., Medhurst C., Sullivan J.F., Ridgway C., Abel S., James I.T., Youle M., van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 2005, 11:1170-1172.
3. Genebat M., Ruiz-Mateos E., León J.A., González-Serna A., Pulido I., Rivas I., Ferrando-Martínez S., Sánchez B., Muñoz-Fernández M.A., Leal M. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J. Antimicrob. Chemother. 2009, 64:845-849.
4. Genebat M., Ruiz-Mateos E., Pulido I., González-Serna A., García-Pergañeda A., Méndez G., Romero-Sánchez M.C., Ferrando-Martínez S., Leal M. Long-term immunovirological effect and tolerability of a maraviroc-containing regimen in routine clinical practice. Curr. HIV Res. 2010, 8:482-486.
5. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., Nadler J., Clotet B., Karlsson A., Wohlfeiler M., Montana J.B., McHale M., Sullivan J., Ridgway C., Felstead S., Dunne M.W., van der Ryst E., Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 2008, 359:1429-1441. MOTIVATE Study Teams.
6. Poveda E., Seclén E., González Mdel M., García F., Chueca N., Aguilera A., Rodríguez J.J., González-Lahoz J., Soriano V. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J. Antimicrob. Chemother. 2009, 63:1006-1010.
7. Recordon-Pinson P., Soulié C., Flandre P., Descamps D., Lazrek M., Charpentier C., Montes B., Trabaud M.-A., Cottalorda J., Schneider V., Morand-Joubert L., Tamalet C., Desbois D., Macé M., Ferré V., Vabret A., Ruffault A., Pallier C., Raymond S., Izopet J., Reynes J., Marcelin A-G., Masquelier B. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS Geno Tropism Study. Antimicrob. Agents Chemother. 2010, 54:3335-3340. the ANRS AC11 Resistance Study Group.
8. Reeves J.D., Coakley E., Petropoulos C.J., Whitcomb J.M. An enhanced-sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J. Viral Entry 2009, 3:94-102.
9. Rozera G., Abbate I., Bruselles A., Vlassi C., D'Offizi G., Narciso P., Chillemi G., Prosperi M., Ippolito G., Capobianchi M.R. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 2009, 6:15.
10. Soulié C., Malet I., Lambert-Niclot S., Tubiana R., Thévenin M., Simon A., Murphy M., Katlama C., Calvez V., Marcelin A.G. Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naïve patients. AIDS 2008, 22:2212-2214.
11. Trouplin V., Salvatori F., Cappello F., Obry V., Brelot A., Heveker N., Alizon M., Scarlatti G., Clavel F., Mammano F. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J. Virol. 2001, 75:251-259.
12. Whitcomb J.M., Huang W., Fransen S., Limoli K., Toma J., Wrin T., Chappey C., Kiss L.D., Paxinos E.E., Petropoulos C.J. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 co-receptor tropism. Antimicrob. Agents Chemother. 2007, 51:556-575.